Skip to main content

PRECISION: DESCIFRANDO LA HETEROGENEIDAD DEL CANCER DE COLON CON IMAGEN DE PRECISION Y APRENDIZAJE AUTOMATICO

PI21/01019

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre FUNDACION PRIVADA INSTITUTO DE INVESTIGACION ONCOLOGICA VALLE DE HEBRON- VHIO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 31
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma

  • Ligero, Marta
  • Carpio Segura, Cecilia del Carmen|||0000-0001-9346-0134
  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Bobillo, Sabela|||0000-0001-7381-680X
  • Marín-Niebla, Ana|||0000-0002-7592-6815
  • Iraola-Truchuelo, Josu|||0000-0002-9909-3715
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Perez-Lopez, Raquel|||0000-0002-9176-0130
  • Barba, Pere|||0000-0001-7076-7969
  • Simó Perdigó, Marc|||0000-0002-3982-8759
  • Balaguer-Montero, Maria
  • Navarro Garcés, Víctor|||0000-0001-6925-4605
  • Sánchez-Salinas, Mario Andrés
  • Sala-Llonch, Roser
Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment option for relapsed or refractory (R/R) large B-cell lymphoma (LBCL). However, only a subset of patients will present long-term benefit. In this study, we explored the potential of PET-based radiomics to predict treatment outcomes with the aim of improving patient selection for CAR T-cell therapy. We conducted a single-center study including 93 consecutive R/R LBCL patients who received a CAR T-cell infusion from 2018 to 2021, split in training set (73 patients) and test set (20 patients). Radiomics features were extracted from baseline PET scans and clinical benefit was defined based on median progression-free survival (PFS). Cox regression models including the radiomics signature, conventional PET biomarkers and clinical variables were performed for most relevant outcomes. A radiomics signature including 4 PET-based parameters achieved an AUC = 0.73 for predicting clinical benefit in the test set, outperforming the predictive value of conventional PET biomarkers (total metabolic tumor volume [TMTV]: AUC = 0.66 and maximum standardized uptake value [SUV]: AUC = 0.59). A high radiomics score was also associated with longer PFS and OS in the multivariable analysis. In conclusion, the PET-based radiomics signature predicted efficacy of CAR T-cell therapy and outperformed conventional PET biomarkers in our cohort of LBCL patients. In patients with large B-cell lymphoma treated with CAR T-cells,radiomics quantification of the PET component allows for better prediction of short term recurrence(3-moths PFS)than conventional SUVmax and Total Metabolic Tumor Volume(TMTV) The combination of Radiomics signature with clinical data allows for better patient stratification.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient

  • Zacchi, Francesca
  • Semidey Raven, Maria Eugenia
  • Maldonado, Xavier
  • Perez-Lopez, Raquel
  • Mateo, Joaquin
  • Macarena, Gonzalez
  • Carles, Joan
Bone metastases; Bone response; Metastatic castration-resistant prostate cancer, Metástasis óseas; Respuesta ósea; Cáncer de próstata resistente a la castración metastásico, Metàstasis òssies; Resposta òssia; Càncer de pròstata resistent a la castració metastàtic, Despite the development of new therapies in the last few years, metastatic prostate cancer (PCa) is still a lethal disease. Radium-223 (Ra-223) is approved for patients with advanced castration-resistant prostate cancer (CRPC) with bone metastases and no visceral disease. However, patients' outcomes are heterogenous, and there is lack of validated predictive biomarkers of response, while biomarkers for early identification of patients who benefit from treatment are limited. This case report describes a remarkable and durable response to Ra-223 in a CRPC patient with bone metastases who had rapidly progressed to many previous therapies; this response is now lasting for 5 years even after having stopped backbone androgen deprivation therapy (ADT). Here, we present the clinical course of this exceptional response, as well as comprehensive genomic and histopathology analyses on sequential biopsies acquired before and after therapy. Additionally, we review current knowledge on predictive and response biomarkers to Ra-223 in metastatic prostate cancer., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors acknowledge funding from CRIS Cancer Foundation (grant TCL_2020-10 to JM) and Fundación AECC (LABAE20019MATE to JM) and FERO Foundation. RP-L is supported by LaCaixa Foundation, a CRIS Foundation Talent Award TALENT19-05, the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud PI18/01395 and PI21/01019 and the Prostate Cancer Foundation 18YOUN19.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Enhancing Tumor Microstructural Quantification With Machine Learning and Diffusion-Relaxation MRI

  • Macarro, Carlos
  • Bernatowicz, Kinga
  • García Ruiz, Alonso
  • Monreal-Agüero, Camilo
  • Corral Gámez, Juanfra
  • Merino Casabiel, Xavier
  • Mast, Richard
  • Serna, Garazi
  • Simonetti, Sara
  • Roson Gradaille, Nuria
  • Vieito , Maria
  • ESCOBAR, MANUEL
  • Toledo, Rodrigo
  • Nuciforo, Paolo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Grussu, Francesco
Cuantificación microestructural de tumores; Aprendizaje automático; Resonancia magnética de difusión-relajación, Quantificació microestructural del tumor; Aprenentatge automàtic; Ressonància magnètica de difusió-relaxació, Tumor microstructural quantification; Machine learning; Diffusion-relaxation magnetic resonance imaging, We thank the whole medical oncology, radiology, pathology, molecular biology, clinical trial, and IT teams at the Vall d'Hebron Campus. We would also like to express our sincere gratitude to all patients and their families for dedicating their time to research. VHIO acknowledges the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support. This research has been supported by PREdICT, sponsored by AstraZeneca. This study has been co-funded by the European Regional Development Fund/European Social Fund “A way to make Europe” (to R.P.L.). RPL is supported by “la Caixa” Foundation, the Prostate Cancer Foundation (18YOUN19), a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation through the XVIII Fero Fellowship for Oncological Research, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR) and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). This research has been funded by the CaixaResearch Advanced Oncology Research Program supported by “La Caixa” Foundation (to R.P.L.). The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010”, funding F.G. This research has received support from the Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP 00182) of the H2020 program (to K.B.). C.M. is supported by the Asociación Española Contra el Cancer (PRYCO211023SERR). VHIO is also grateful to the Generalitat de Catalunya, Comissió Interdepartamental de Recerca i Innovació Tecnològica.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI

  • Palombo, Marco
  • Navarro-Garcia, Daniel
  • Macarro, Carlos
  • Merino Casabiel, Xavier
  • Mast, Richard
  • Grussu, Francesco
  • Grigoriou, Athanasios
  • Bernatowicz, Kinga
  • Casanova-Salas, Irene
  • Barba, Ignasi
  • Simonetti, Sara
  • Serna, Garazi
  • Voronova, Anna
  • Corral Gámez, Juanfra
  • Roson Gradaille, Nuria
  • ESCOBAR, MANUEL
  • Vieito , Maria
  • Toledo, Rodrigo
  • Nuciforo, Paolo
  • Mateo, Joaquin
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
Liver tumour cell; In vivo diffusion MRI, Células tumorales hepáticas; Resonancia magnética de difusión in vivo, Cèl·lules tumorals hepàtiques; Ressonància magnètica de difusió in vivo, Background: Innovative diffusion Magnetic Resonance Imaging (MRI) models enable the non-invasive measurement of cancer biological properties in vivo. However, while cancers frequently spread to the liver, models tailored for liver application and easy to deploy in the clinic are still sought. We fill this gap by delivering a practical, clinically-viable framework for liver tumour diffusion imaging, informing its design through histology. Methods: We compare MRI and histological data from mice and cancer patients, namely: MRI and hemaotxylin-eosin (HE) stains from N = 7 fixed mouse livers; MRI of N = 38 patients suffering from liver solid tumours, N = 18 of whom with HE biopsies. We study five diffusion models, ranking them according to a total MRI-histology correlation score. Afterwards, we test metrics from the top-ranking model on our cohort, assessing their sensitivity to cell proliferation (Ki-67 staining, N = 10), evaluating their association with tumour volume (N = 140 tumours), and comparing them across primary cancer types. Results: We select a dMRI signal model of restricted intra-cellular diffusion with negligible extra-cellular contributions, which maximises radiological-histological correlations (total score: 0.625). The model provides cell size and density estimates that i) correlate with histology (e.g., for cell size: r = 0.44, p = 0.029), ii) are associated to Ki-67 cell proliferation (for MRI cell density: r = 0.80, p = 0.006) and tumour volume (r = 0.40, p < 10-5 for tumour volume regression), and iii) that distinguish melanoma (N = 8) from colorectal cancer (N = 13) (p = 0.011 for intra-cellular fraction). Conclusions: Our biologically meaningful approach may complement standard-of-care radiology, and become a new tool for enhanced cancer characterisation in precision oncology., We thank the whole medical oncology, radiology, pathology, molecular biology, clinical trial, and IT teams at the Vall d’Hebron University Hospital and at the Vall d’Hebron Institute of Oncology in Barcelona (Spain), without whom this study would not have been possible. We are also thankful to the Vall d’Hebron Radiology department and to the ASCIRES CETIR clinical team for their assistance, and to past and present members of the Radiomics group for useful discussion and advice. Finally, we would like to express our sincere gratitude to all patients and their families for dedicating their time to research. VHIO would like to acknowledge: the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support on this research. This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project “PI21/01019” and co-funded by the European Union. Data acquisition was also supported by PREdICT, sponsored by AstraZeneca. This study has been co-funded by the European Regional Development Fund/European Social Fund ‘A way to make Europe’ (to R.P.L.), and by the Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI), funded by the Banco Bilbao Vizcaya Argentaria Foundation Foundation (FBBVA, grant 89/2017). R.P.L is supported by the “la Caixa” Foundation CaixaResearch Advanced Oncology Research Program, the Prostate Cancer Foundation (18YOUN19), ISCIII (PI18/01395), a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation through the XVIII Fero Fellowship for Oncological Research, the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR) and the Generalitat de Catalunya Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). The project that gave rise to these results received the support of a fellowship from”la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010” (funding F.G. and A.V.) and “LCF/BQ/PI20/11760033” (funding I.C.S). I.C.S. also receives the support of the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 847648. This research has received support from the Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP 00182) of the H2020 program (to K.B.). M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/2. A.G. is supported by a Severo Ochoa PhD fellowship (PRE2022-102586). C.M. is funded by the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR). Funding supported personnel, data acquisition and processing, and dissemination. Funders did not influence the content of the manuscript and the decision to submit it in its current form for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response

  • Navarro-Garcia, Daniel
  • Klümper, Niklas
  • Macarro, Carlos
  • Sanz, Marta
  • Alonso, Guzman
  • Lostes Bardaji, M Julia
  • Grussu, Francesco
  • Zatse, Christina
  • Hernando-Calvo, Alberto
  • Vieito , Maria
  • Brana, Irene
  • Mirallas, Oriol
  • Galvao, Vladimir
  • Pretelli, Giulia
  • Oberoi, Arjun
  • Toledo, Rodrigo
  • Nuciforo, Paolo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
Biomarcador; Inhibidor de puntos de control inmunitario; Inmunoterapia, Biomarcador; Inhibidor del punt de control immunitari; Immunoteràpia, Biomarker; Immune checkpoint inhibitor; Immunotherapy, Background The C-reactive protein (CRP) flare response, an indicator of early immune activation, has emerged as a promising and cost-effective biomarker for predicting response to immune checkpoint inhibitors (ICIs) across various tumor types. This study evaluates the utility of CRP dynamics as a tumor-agnostic biomarker and integrates systemic inflammatory markers with advanced multiparametric MRI metrics to uncover the biological mechanisms underlying the CRP flare phenomenon and its relationship with treatment response. Methods Patients were stratified into three groups based on CRP kinetics: (1) flare-responders, characterized by an initial doubling of baseline CRP followed by a decrease below baseline; (2) CRP responders, defined as patients with no flare increase but a CRP reduction of at least 30% below baseline and (3) CRP non-responders. Multiparametric MRI was performed at baseline, early (1–3 weeks), and intermediate (6–8 weeks) time points to assess tumor size and microstructural features, including cell density and vascularization. Clinical benefit and survival outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed using Kaplan-Meier curves and log-rank tests. Cox regression analyses were performed to identify independent predictors of clinical outcomes, while intergroup differences in MRI metrics were assessed using Wilcoxon rank-sum and Kruskal-Wallis tests. Results Among the 121 evaluable patients with solid tumors enrolled in the PREDICT trial, CRP flare-responders demonstrated significantly longer PFS (5.6 months) and OS (12.1 months) compared with responders (PFS: 3.4 months, OS: 8.0 months) and non-responders (PFS: 3.2 months, OS: 6.7 months; p=0.01 and p<0.01, respectively). Additionally, clinical benefit was achieved in 50% of flare-responders, compared with 13% of responders (p=0.05) and 23% of non-responders (p<0.01). Tumor growth was interrupted early after treatment initiation in CRP flare-responders, whereas non-responders exhibited marked increases in tumor size. In the pilot subset of 33 patients with MRI data, diffusion MRI revealed stable or increased apparent diffusion coefficient values in CRP flare-responders, indicative of reduced tumor cellularity just after 1–3 weeks of treatment. Conclusions This study highlights the potential of combining early CRP dynamics with non-invasive imaging metrics to identify ICI responders as early as 2 weeks after treatment initiation. By integrating systemic inflammatory biomarkers with MRI-derived insights into tumor size and microstructural changes, these findings optimize therapeutic strategies and advance understanding of immunotherapy-driven tumor dynamics., This research has been supported by PREDICT sponsored by AstraZeneca. RP-L is also supported by a CRIS Foundation Talent Award (TALENT19-05), Asociacion Espanola Contra el Cancer (AECC) (PRYCO211023SERR), the FERO Foundation, “la Caixa” Foundation, Instituto de Salud Carlos III-Investigación en Salud (PI21/01019), and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). FG receives the support of a fellowship from "la Caixa" Foundation (ID 100010434). The fellowship code is "LCF/BQ/PR22/11920010". Vall d’Hebron Institut d’Oncologia (VHIO) authors would like to acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for financial support as a Centre of Excellence Severo Ochoa (CEX2020-001024-S/AEI/ 10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, and the Generalitat de Catalunya CERCA Programme for their support of this research. We would like to acknowledge all the patients who participated in this and other clinical research projects for their contribution to science. AHC would like to acknowledge Contrato Rio Hortega 2024 and Beca Gilead a la Investigación Biomedica.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking?

  • Gielen, Bente
  • Prior, Olivia
  • Ligero, Marta
  • Dienstmann, Rodrigo
  • Nuciforo, Paolo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Cresta Morgado, Pablo
  • Navarro Garces, Victor
Biomarkers; Immunotherapy; Cancer, Biomarcadors; Immunoteràpia; Càncer, Biomarcadores; Inmunoterapia; Cáncer, The search for understanding immunotherapy response has sparked interest in diverse areas of oncology, with artificial intelligence (AI) and radiomics emerging as promising tools, capable of gathering large amounts of information to identify suitable patients for treatment. The application of AI in radiology has grown, driven by the hypothesis that radiology images capture tumor phenotypes and thus could provide valuable insights into immunotherapy response likelihood. However, despite the rapid growth of studies, no algorithms in the field have reached clinical implementation, mainly due to the lack of standardized methods, hampering study comparisons and reproducibility across different datasets. In this review, we performed a comprehensive assessment of published data to identify sources of variability in radiomics study design that hinder the comparison of the different model performance and, therefore, clinical implementation. Subsequently, we conducted a use-case meta-analysis using homogenous studies to assess the overall performance of radiomics in estimating programmed death-ligand 1 (PD-L1) expression. Our findings indicate that, despite numerous attempts to predict immunotherapy response, only a limited number of studies share comparable methodologies and report sufficient data about cohorts and methods to be suitable for meta-analysis. Nevertheless, although only a few studies meet these criteria, their promising results underscore the importance of ongoing standardization and benchmarking efforts. This review highlights the importance of uniformity in study design and reporting. Such standardization is crucial to enable meaningful comparisons and demonstrate the validity of biomarkers across diverse populations, facilitating their implementation into the immunotherapy patient selection process., This research has been funded by the Comprehensive Program of Cancer Immunotherapy & Immunology II (CAIMI-II) supported by the BBVA Foundation (grant 53/2021). RPL is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019), the Prostate Cancer Foundation (18YOUN19) and the Asociacion Española Contra el Cancer (AECC) (PRYCO211023SERR). ML is supported by the PERIS PIF-Salut Grant. OP is supported by a La Caixa INPhINIT Fellowship.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

ESR Essentials: diffusion-weighted MRI—practice recommendations by the European Society for Magnetic Resonance in Medicine and Biology

  • Palombo, Marco
  • Tang, Guoheng
  • Le Bihan, Denis
  • Nilsson, Markus
  • Grussu, Francesco
  • Perez-Lopez, Raquel
Diffusion magnetic resonance imaging; Human body; Human brain, Resonancia magnética de difusión; Cuerpo humano; Cerebro humano, Ressonància magnètica de difusió; Cos humà; Cervell humà, Diffusion-weighted imaging (DWI) offers critical insights into tissue microstructure through the assessment of water molecule random displacements and plays a central role in the assessment of neoplastic and non-neoplastic diseases. To successfully implement and use DWI in clinical practice, guidelines for acquisition, interpretation of image contrast and of artefacts should be followed, taking the disease process and body part into account. We recommend covering a b-value range of 0–1000 s/mm2 in the brain (along at least six directions for white matter), and 50–800 s/mm2 in the body. Available acquisition acceleration options should be used to reduce repetition time (TR), echo time (TE), and echo-planar imaging (EPI) distortions, while considering the penalty in signal-to-noise ratio (SNR) and image sharpness. DW images and the apparent diffusion coefficient (ADC) map should be read jointly for the clinical interpretation. Areas of slower diffusion are hyperintense on DW images and hypointense on the ADC map, and vice versa. Magnetic susceptibility distortions and signal drop-outs or pile-ups are particularly pronounced at air-tissue or metal-tissue interfaces and may obscure areas of interest or hinder the co-localisation with structural scans. By following these guidelines and recommendations, radiologists and imaging professionals can enhance diagnostic accuracy, reduce variability, and maximise the clinical value of DWI across diverse applications. Key Points This article provides an overview of DWI principles, clinical applications, potential pitfalls, and emerging advances, alongside expert recommendations for optimal implementation. We provide key considerations tailored to specific applications (neuro and whole-body imaging), including protocol optimisation, adherence to established guidelines, and quality assurance measures to minimise artefacts and ensure reproducibility. By following the guidelines and recommendations summarised in this work, radiologists and imaging professionals can enhance diagnostic accuracy, reduce variability, and maximise the clinical value of DWI across diverse applications., The authors state that this work has not received any funding. M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/2 and the Medical Research Council research grant MR/W031566/1. R.P.-L. is supported by ‘la Caixa’ Foundation, a CRIS Cancer Foundation Talent Award (TALENT19-05), the Instituto de Salud Carlos III-Investigación en Salud (PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR), and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). F.G. receives the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010”. I.O.J. is supported by the SNSF Eccellenza fellowship #194260. M.N. is supported by the Swedish Cancer Foundation (FO2024-0335-HK-73) and the Swedish Science Council (2024-04968).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction

  • Zatse, Christina
  • Garazi, Serna
  • Bernatowicz, Kinga
  • Amat Ferrer, Ramon
  • Prior, Olivia
  • Frigola Rissech, Joan
  • Ligero, Marta
  • Grussu, Francesco
  • Nuciforo, Paolo
  • Toledo, Rodrigo
  • ESCOBAR, MANUEL
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • FELIP, ENRIQUETA
Computed tomography; Immunotherapy; Tumor microenvironment, Tomografía computarizada; Inmunoterapia; Microambiente tumoral, Tomografia computeritzada; Immunoteràpia; Microambient tumoral, Background: The efficacy of immune checkpoint inhibitors (ICIs) depends on the tumor immune microenvironment (TIME), with a preference for a T cell-inflamed TIME. However, challenges in tissue-based assessments via biopsies have triggered the exploration of non-invasive alternatives, such as radiomics, to comprehensively evaluate TIME across diverse cancers. To address these challenges, we develop an ICI response signature by integrating radiomics with T cell-inflamed gene-expression profiles. Methods: We conducted a pan-cancer investigation into the utility of radiomics for TIME assessment, including 1360 tumors from 428 patients. Leveraging contrast-enhanced CT images, we characterized TIME through RNA gene expression analysis, using the T cell-inflamed gene expression signature. Subsequently, a pan-cancer CT-radiomic signature predicting inflamed TIME (CT-TIME) was developed and externally validated. Machine learning was employed to select robust radiomic features and predict inflamed TIME. The study also integrated independent cohorts with longitudinal CT images, baseline biopsies, and comprehensive immunohistochemistry panel evaluation to assess the pan-cancer biological associations, spatiotemporal landscape and clinical utility of the CT-TIME. Results: The CT-TIME signature, comprising four radiomic features linked to a T-cell inflamed microenvironment, demonstrated robust performance with AUCs (95% CI) of 0.85 (0.73 to 0.96) (training) and 0.78 (0.65 to 0.92) (external validation). CT-TIME scores exhibited positive correlations with CD3, CD8, and CD163 expression. Intrapatient analysis revealed considerable heterogeneity in TIME between tumors, which could not be assessed using biopsies. Evaluation of aggregated per-patient CT-TIME scores highlighted its promising clinical utility for dynamically assessing the immune microenvironment and predicting immunotherapy response across diverse scenarios in advanced cancer. Despite demonstrating progression disease at the first follow-up, patients within the inflamed status group, identified by CT-TIME, exhibited significantly prolonged progression-free survival (PFS), with some surpassing 5 months, suggesting a potential phenomenon of pseudoprogression. Cox models using aggregated CT-TIME scores from baseline images revealed a statistically significant reduction in the risk of PFS in the pan-cancer cohort (HR 0.62, 95% CI 0.44 to 0.88, p=0.007), and Kaplan-Meier analysis further confirmed substantial differences in PFS between patients with inflamed and uninflamed status (log-rank test p=0.009). Conclusions: The signature holds promise for impacting clinical decision-making, pan-cancer patient stratification, and treatment outcomes in immune checkpoint therapies., KB is supported by MSCA COFUND Beatriu de Pinós Grant (2019BP/00182). FG receives the support of a fellowship from LaCaixa Foundation (ID 100010434). The fellowship code is LCF/BQ/PR22/11920010. RP-L is supported by CRIS Cancer Foundation (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019) and the Prostate Cancer Foundation (18YOUN19). OP was funded by Fundació “LaCaixa” (ID 100010434, code LCF/BQ/DR21/11880027).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A framework for artificial intelligence in cancer research and precision oncology

  • Perez-Lopez, Raquel
  • Reis-Filho, Jorge S.
  • Kather, Jakob Nikolas
Artificial intelligence; Precision oncology, Intel·ligència artificial; Oncologia de precisió, Inteligencia artificial; Oncología de precisión, R.P.L. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019), the Prostate Cancer Foundation (18YOUN19) and the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR, funding C.M.). J.N.K. is supported by the German Federal Ministry of Health (DEEP LIVER, ZMVI1-2520DAT111) and the Max-Eder-Program of the German Cancer Aid (grant #70113864), the German Federal Ministry of Education and Research (PEARL, 01KD2104C; CAMINO, 01EO2101; SWAG, 01KD2215A; TRANSFORM LIVER, 031L0312A; TANGERINE, 01KT2302 through ERA-NET Transcan), the German Academic Exchange Service (SECAI, 57616814), the German Federal Joint Committee (Transplant.KI, 01VSF21048) the European Union’s Horizon Europe and innovation program (ODELIA, 101057091; GENIAL, 101096312) and the National Institute for Health and Care Research (NIHR, NIHR213331) Leeds Biomedical Research Centre. JSR-F is funded in part by the Breast Cancer Research Foundation, a Susan G Komen Leadership grant, an NIH/NCI P50 CA247749 01 grant, and an NIH/NCI grant No. P30CA008748. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy

  • Castillo, Gloria
  • Martinez Perez, Paola
  • Gonzalez Medina, Alberto
  • Vila-Casadesús, Maria
  • Gómez-Rey, Marina
  • Fabregat Franco, Carles
  • TIAN, TIAN
  • Castet, Florian
  • Matito, Judit
  • Miquel Aymar, Josep Maria
  • Nuciforo, Paolo
  • Perez-Lopez, Raquel
  • Vivancos, Ana
  • SIERRA, ALEXANDRE
  • Macarulla, Teresa
Liquid biopsy; Cholangiocarcinoma; Targeted therapy, Biopsia líquida; Colangiocarcinoma; Terapia dirigida, Biòpsia líquida; Colangiocarcinoma; Teràpia dirigida, Purpose: FGFR2 fusions occur in 10% to 15% of patients with intrahepatic cholangiocarcinoma (iCCA), potentially benefiting from FGFR inhibitors (FGFRi). We aimed to assess the feasibility of detecting FGFR2 fusions in plasma and explore plasma biomarkers for managing FGFRi treatment. Experimental design: We conducted a retrospective study in 18 patients with iCCA and known FGFR2 fusions previously identified in tissue samples from prior FGFRi treatment. Both tissue and synchronous plasma samples were analyzed using a custom hybrid capture gene panel with next-generation sequencing (VHIO-iCCA panel) and validated against commercial vendor results. Longitudinal plasma analysis during FGFRi was performed. Subsequently, we explored the correlation between plasma biomarkers, liver enzymes, tumor volume, and clinical outcomes. Results: Sixteen patients (88.9%) were positive for FGFR2 fusion events in plasma. Remarkably, the analysis of plasma suggests that lower levels of ctDNA are linked to clinical benefits from targeted therapy and result in improved progression-free survival and overall survival. Higher concentrations of cell-free DNA before FGFRi treatment were linked to worse overall survival, correlating with impaired liver function and indicating compromised cell-free DNA removal by the liver. Additionally, increased ctDNA or the emergence of resistance mutations allowed earlier detection of disease progression compared with standard radiologic imaging methods. Conclusions: VHIO-iCCA demonstrated accurate detection of FGFR2 fusions in plasma. The integration of information from various plasma biomarkers holds the potential to predict clinical outcomes and identify treatment failure prior to radiologic progression, offering valuable guidance for the clinical management of patients with iCCA., This study was supported by Incyte Corporation (Wilmington, DE; project title: “Identification of FGFR2 alterations by liquid biopsy and correlation with tissue biopsies in patients with cholangiocarcinoma”), the Asociación Española contra el Cáncer (AECC, Spain), and the FERO Foundation. A. Gonzalez-Medina is supported by the grant FJC2019-039770-I funded by Agencia Estatal de Investigación of Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033, Spain). R. Pérez-López. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Prostate Cancer Foundation (18YOUN19), and the Asociación Española Contra el Cáncer (AECC; PRYCO211023SERR, funding CM). A. Vivancos is supported by the Instituto de Salud Carlos III-investigación en Salud (PI20/01112). Some pictures were created with BioRender.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer

  • Balaguer-Montero, Maria
  • Marcos Morales, Adrià
  • Leiva, David
  • Atlagich, Luz M.
  • Staikoglou, Nikolaos
  • Monreal, Camilo
  • Hernando, Jorge
  • Garcia-Alvarez, Alejandro
  • Ligero, Marta
  • Zatse, Christina
  • Viaplana, Cristina
  • Mateo, Joaquin
  • Salvà, Francesc
  • Capdevila Castillon, Jaume
  • Dienstmann, Rodrigo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Elez, Elena
Deep learning; Imaging; Liver tumors, Aprendizaje profundo; Imágenes; Tumores hepáticos, Aprenentatge profund; Imatges; Tumors hepàtics, Liver tumors, whether primary or metastatic, significantly impact the outcomes of patients with cancer. Accurate identification and quantification are crucial for effective patient management, including precise diagnosis, prognosis, and therapy evaluation. We present SALSA (system for automatic liver tumor segmentation and detection), a fully automated tool for liver tumor detection and delineation. Developed on 1,598 computed tomography (CT) scans and 4,908 liver tumors, SALSA demonstrates superior accuracy in tumor identification and volume quantification, outperforming state-of-the-art models and inter-reader agreement among expert radiologists. SALSA achieves a patient-wise detection precision of 99.65%, and 81.72% at lesion level, in the external validation cohorts. Additionally, it exhibits good overlap, achieving a dice similarity coefficient (DSC) of 0.760, outperforming both state-of-the-art and the inter-radiologist assessment. SALSA’s automatic quantification of tumor volume proves to have prognostic value across various solid tumors (p = 0.028). SALSA’s robust capabilities position it as a potential medical device for automatic cancer detection, staging, and response evaluation., R.P.-L. is supported by “la Caixa” Foundation, a CRIS Cancer Foundation Talent Award (TALENT19-05), the Fero Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR), and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

  • Ros Montañá, Fco. Javier
  • Fernández, Jose
  • Moreno-Cárdenas, Ana Belén
  • Arenillas Lallana, Carlota
  • Fasani, Roberta
  • Garcia Rodriguez, Ariadna
  • Gonzalo-Ruiz, Javier
  • Nuciforo, Paolo Giovanni
  • Vivancos Prellezo, Ana
  • Pérez López, Raquel
  • Tabernero, Josep
  • De Almeida Toledo, Rodrigo
  • Comas Navarro, Raquel
  • Dienstmann, Rodrigo
  • Bernatowicz, Kinga
  • Piris-Giménez, Alejandro
  • Elez Fernandez, Mª Elena
  • Villacampa Javierre, Guillermo
Colorectal cancer; Predictive markers; Tumour biomarkers, Cáncer colorrectal; Marcadores predictivos; Biomarcadores tumorales, Càncer colorrectal; Marcadors predictius; Biomarcadors tumorals, Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; P = 0.008), in patients with MSS-RNF43mutated versus MSS-RNF43wild-type tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRCBRAF-V600E tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients., VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment, the FERO Foundation for their funding support, the Consorcio Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, CB16/12/00259) from the Institute of Health Carlos III (ISCIII), Ministry of Science and Innovation, and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 and SLT008/18/00205) for their support on this research. Authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S / AEI / 10.13039 /501100011033). This research is funded by the SCITRON program; Novartis funded the genomics characterization by WES of samples from 28 patients from the discovery cohort and had no influence on data analysis/interpretation or writing of the paper (3003145512 to R.A.T.). S.Li. is financially supported by a Chinese Scholarship Council PhD fellowship (201909370083 to S. Li). R.P.-L. is supported by a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019 to R.P.-L.) and the Prostate Cancer Foundation (Young Investigator Award). This work was supported by the Miguel Servet-I Research Award from ISCIII of the Ministry of Economy (CP17/00199 to R.A.T.), the Olga Torres Foundation Award to emerging researchers (2601 to R.A.T.), the ISCIII-FEDER (PI17/00947 and PI20/00968 to E.E.), and the Fundación AECC (CLSEN19001ELEZ to E.E.) and Ministry of Science and Innovation (Europa Redes y Gestores, ECT2020-000827 to E.E.).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

SpinFlowSim: A blood flow simulation framework for histology-informed diffusion MRI microvasculature mapping in cancer

  • Novikov, Dmitry
  • Grigoriou, Athanasios
  • Bernatowicz, Kinga
  • Simonetti, Sara
  • Serna, Garazi
  • Roson Gradaille, Nuria
  • ESCOBAR, MANUEL
  • Vieito , Maria
  • Nuciforo, Paolo
  • Toledo, Rodrigo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Grussu, Francesco
Cancer; Capillary flow; Diffusion MRI, Cáncer; Flujo capilar; Resonancia magnética de difusión, Càncer; Flux capil·lar; Ressonància magnètica de difusió, Diffusion Magnetic Resonance Imaging (dMRI) sensitises the MRI signal to spin motion. This includes Brownian diffusion, but also flow across intricate networks of capillaries. This effect, the intra-voxel incoherent motion (IVIM), enables microvasculature characterisation with dMRI, through metrics such as the vascular signal fraction or the vascular Apparent Diffusion Coefficient (ADC) . The IVIM metrics, while sensitive to perfusion, are protocol-dependent, and their interpretation can change depending on the flow regime spins experience during the dMRI measurements (e.g., diffusive vs ballistic), which is in general not known for a given voxel. These facts hamper their practical clinical utility, and innovative vascular dMRI models are needed to enable the in vivo calculation of biologically meaningful markers of capillary flow. These could have relevant applications in cancer, as in the assessment of the response to anti-angiogenic therapies targeting tumour vessels. This paper tackles this need by introducing SpinFlowSim, an open-source simulator of dMRI signals arising from blood flow within pipe networks. SpinFlowSim, tailored for the laminar flow patterns within capillaries, enables the synthesis of highly-realistic microvascular dMRI signals, given networks reconstructed from histology. We showcase the simulator by generating synthetic signals for 15 networks, reconstructed from liver biopsies, and containing cancerous and non-cancerous tissue. Signals exhibit complex, non-mono-exponential behaviours, consistent with in vivo signal patterns, and pointing towards the co-existence of different flow regimes within the same network, as well as diffusion time dependence. We also demonstrate the potential utility of SpinFlowSim by devising a strategy for microvascular property mapping informed by the synthetic signals, and focussing on the quantification of blood velocity distribution moments and of an apparent network branching index. These were estimated in silico and in vivo, in healthy volunteers scanned at 1.5T and 3T and in 13 cancer patients, scanned at 1.5T. In conclusion, realistic flow simulations, as those enabled by SpinFlowSim, may play a key role in the development of the next-generation of dMRI methods for microvascular mapping, with immediate applications in oncology., VHIO would like to acknowledge: the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support on this research. This research has been supported by PREdICT, sponsored by AstraZeneca. This study has been co-funded by the European Regional Development Fund/European Social Fund ‘A way to make Europe’ (to R.P.L.), and by the Comprehensive Program of Cancer Immunotherapy and Immunology (CAIMI), funded by the Banco Bilbao Vizcaya Argentaria Foundation Foundation (FBBVA, grant 89/2017). R.P.L. is supported by the “la Caixa” Foundation CaixaResearch Advanced Oncology Research Program, the Prostate Cancer Foundation (18YOUN19), a CRIS Foundation Talent Award (TALENT19-05, the FERO Foundation through the XVIII Fero Fellowship for Oncological Research, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR) and the Generalitat de Catalunya Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178, SGR-Cat2021). The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010” (funding F.G., A.V., and A.G.). This research has received support from the Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP 00182) of the H2020 program (to K.B.). M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/2. A.G. is supported by a Severo Ochoa PhD fellowship (PRE2022-102586). The authors are thankful to the Vall d’Hebron Radiology department and to the ASCIRES CETIR clinical team for their assistance with MRI acquisitions, and to the GE/Siemens clinical scientists for their support with diffusion sequence characterisation. We are also thankful to patients and their families, and to Prof Roser Sala-Llonch from the University of Barcelona for useful discussion and institutional support.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

An accessible deep learning tool for voxel-wise classification of brain malignancies from perfusion MRI

  • Garcia Ruiz, Alonso
  • Pons-Escoda, Albert
  • Naval-Baudin, Pablo
  • Monreal-Aguero, Camilo
  • Hermann, Gretchen
  • Grussu, Francesco
  • Ligero, Marta
  • Perez-Lopez, Raquel
Deep learning; Glioblastoma; Perfusion MRI, Aprenentatge profund; Glioblastoma; Ressonància magnètica de perfusió, Aprendizaje profundo; Glioblastoma; Resonancia magnética de perfusión, Noninvasive differential diagnosis of brain tumors is currently based on the assessment of magnetic resonance imaging (MRI) coupled with dynamic susceptibility contrast (DSC). However, a definitive diagnosis often requires neurosurgical interventions that compromise patients' quality of life. We apply deep learning on DSC images from histology-confirmed patients with glioblastoma, metastasis, or lymphoma. The convolutional neural network trained on ∼50,000 voxels from 40 patients provides intratumor probability maps that yield clinical-grade diagnosis. Performance is tested in 400 additional cases and an external validation cohort of 128 patients. The tool reaches a three-way accuracy of 0.78, superior to the conventional MRI metrics cerebral blood volume (0.55) and percentage of signal recovery (0.59), showing high value as a support diagnostic tool. Our open-access software, Diagnosis In Susceptibility Contrast Enhancing Regions for Neuro-oncology (DISCERN), demonstrates its potential in aiding medical decisions for brain tumor diagnosis using standard-of-care MRI., This project was supported by “La Caixa” Foundation (RTI2018-095209-B-C21) and the Spanish Ministry of Science and Innovation (FIS-G64384969). R.P.-L. is supported by the Prostate Cancer Foundation Young Investigator Award, the FERO Foundation, the CRIS Foundation Talent Award (TALENT19-05), the Instituto de Salud Carlos III Investigacion en Salud (PI21/01019), and the Asociacion Espanola Contra el Cancer (PRYCO211023SERR). F.G. was funded by the Government of Catalonia (Beatriu de Pinos 2020 00117 BP) and by the Fundacio LaCaixa (ID 100010434, code LCF/BQ/PR22/11920010). C.M. and A.P.-E. acknowledge support from the Instituto de Salud Carlos III-Investigación en Salud (PI20/00360). We would like to express our sincere appreciation to Javier Carmona for his valuable support and assistance in reviewing the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study

  • Ramlee, Syafiq
  • Hulse, David
  • Pérez López, Raquel
  • Sala, Evis
  • Aloj, Luigi
  • Bernatowicz, Kinga
Cancer; Immune cells; Lymphocytes, Cáncer; Células inmunes; Linfocitos, Càncer; Cèl·lules immunitàries; Limfòcits, The tumour immune microenvironment influences the efficacy of immune checkpoint inhibitors. Within this microenvironment are CD8-expressing tumour-infiltrating lymphocytes (CD8+ TILs), which are an important mediator and marker of anti-tumour response. In practice, the assessment of CD8+ TILs via tissue sampling involves logistical challenges. Radiomics, the high-throughput extraction of features from medical images, may offer a novel and non-invasive alternative. We performed a systematic review of the available literature reporting radiomic signatures associated with CD8+ TILs. We also aimed to evaluate the methodological quality of the identified studies using the Radiomics Quality Score (RQS) tool, and the risk of bias and applicability with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Articles were searched from inception until 31 December 2021, in three electronic databases, and screened against eligibility criteria. Twenty-seven articles were included. A wide variety of cancers have been studied. The reported radiomic signatures were heterogeneous, with very limited reproducibility between studies of the same cancer group. The overall quality of studies was found to be less than desirable (mean RQS = 33.3%), indicating a need for technical maturation. Some potential avenues for further investigation are also discussed., This work was supported by the Cancer Research UK (CRUK) Cambridge Centre (CTRQQR-2021\100012) and the CRUK National Cancer Imaging Translational Accelerator (NCITA) (C22479/A28667); additional support was also provided by the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014); the views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care; S.R. is supported by the Brunei “Sultan’s Scholar” scholarship from the Sultan Haji Hassanal Bolkiah Foundation; D.H. is supported by the Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies project (RG96994 and 831514); K.B. is supported by MSCA COFUND Beatriu de Pinós Grant (2019BP/00182); R.P.L. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019) and the Prostate Cancer Foundation (18YOUN19).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

  • Ligero, Marta
  • El Nahhas, Omar
  • SANSANO, IRENE
  • Mauchanski, Siarhei
  • Serna, Garazi
  • Viaplana, Cristina
  • Toledo, Rodrigo
  • Dienstmann, Rodrigo
  • Ramon y Cajal, Santiago
  • GARRALDA, Elena
  • Nuciforo, Paolo
  • Perez-Lopez, Raquel
Deep learning; Immunotherapy; Solid tumors, Aprenentatge profund; Immunoteràpia; Tumors sòlids, Aprendizaje profundo; Inmunoterapia; Tumores sólidos, Programmed death-ligand 1 (PD-L1) IHC is the most commonly used biomarker for immunotherapy response. However, quantification of PD-L1 status in pathology slides is challenging. Neither manual quantification nor a computer-based mimicking of manual readouts is perfectly reproducible, and the predictive performance of both approaches regarding immunotherapy response is limited. In this study, we developed a deep learning (DL) method to predict PD-L1 status directly from raw IHC image data, without explicit intermediary steps such as cell detection or pigment quantification. We trained the weakly supervised model on PD-L1–stained slides from the non–small cell lung cancer (NSCLC)-Memorial Sloan Kettering (MSK) cohort (N = 233) and validated it on the pan-cancer-Vall d'Hebron Institute of Oncology (VHIO) cohort (N = 108). We also investigated the performance of the model to predict response to immune checkpoint inhibitors (ICI) in terms of progression-free survival. In the pan-cancer-VHIO cohort, the performance was compared with tumor proportion score (TPS) and combined positive score (CPS). The DL model showed good performance in predicting PD-L1 expression (TPS ≥ 1%) in both NSCLC-MSK and pan-cancer-VHIO cohort (AUC 0.88 ± 0.06 and 0.80 ± 0.03, respectively). The predicted PD-L1 status showed an improved association with response to ICIs [HR: 1.5 (95% confidence interval: 1–2.3), P = 0.049] compared with TPS [HR: 1.4 (0.96–2.2), P = 0.082] and CPS [HR: 1.2 (0.79–1.9), P = 0.386]. Notably, our explainability analysis showed that the model does not just look at the amount of brown pigment in the IHC slides, but also considers morphologic factors such as lymphocyte conglomerates. Overall, end-to-end weakly supervised DL shows potential for improving patient stratification for cancer immunotherapy by analyzing PD-L1 IHC, holistically integrating morphology and PD-L1 staining intensity. Significance: The weakly supervised DL model to predict PD-L1 status from raw IHC data, integrating tumor staining intensity and morphology, enables enhanced patient stratification in cancer immunotherapy compared with traditional pathologist assessment., J.N. Kather is supported by the German Federal Ministry of Health (DEEP LIVER, ZMVI1-2520DAT111) and the Max-Eder-Programme of the German Cancer Aid (grant no. 70113864), the German Federal Ministry of Education and Research (PEARL, 01KD2104C; CAMINO, 01EO2101; SWAG, 01KD2215A; TRANSFORM LIVER, 031L0312A; TANGERINE, 01KT2302 through ERA-NET Transcan), the German Academic Exchange Service (SECAI, 57616814), the German Federal Joint Committee (Transplant.KI, 01VSF21048) the European Union's Horizon Europe and innovation programme (ODELIA, 101057091; GENIAL, 101096312) and the National Institute for Health and Care Research (NIHR, NIHR213331) Leeds Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. R. Perez-Lopez is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019) and the Prostate Cancer Foundation (18YOUN19). M. Ligero is supported by the PERIS PIF-Salut Grant. As per the ICMJE guidelines of April 2023, we hereby disclose that the following artificial intelligence tools were used to write this article: ChatGPT-4 for checking and correcting spelling and grammar.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

ESR Essentials: diffusion-weighted MRI—practice recommendations by the European Society for Magnetic Resonance in Medicine and Biology

  • Palombo, Marco
  • Tang, Guoheng
  • Le Bihan, Denis
  • Nilsson, Markus
  • Grussu, Francesco
  • Perez-Lopez, Raquel
Diffusion magnetic resonance imaging; Human body; Human brain, Resonancia magnética de difusión; Cuerpo humano; Cerebro humano, Ressonància magnètica de difusió; Cos humà; Cervell humà, Diffusion-weighted imaging (DWI) offers critical insights into tissue microstructure through the assessment of water molecule random displacements and plays a central role in the assessment of neoplastic and non-neoplastic diseases. To successfully implement and use DWI in clinical practice, guidelines for acquisition, interpretation of image contrast and of artefacts should be followed, taking the disease process and body part into account. We recommend covering a b-value range of 0–1000 s/mm2 in the brain (along at least six directions for white matter), and 50–800 s/mm2 in the body. Available acquisition acceleration options should be used to reduce repetition time (TR), echo time (TE), and echo-planar imaging (EPI) distortions, while considering the penalty in signal-to-noise ratio (SNR) and image sharpness. DW images and the apparent diffusion coefficient (ADC) map should be read jointly for the clinical interpretation. Areas of slower diffusion are hyperintense on DW images and hypointense on the ADC map, and vice versa. Magnetic susceptibility distortions and signal drop-outs or pile-ups are particularly pronounced at air-tissue or metal-tissue interfaces and may obscure areas of interest or hinder the co-localisation with structural scans. By following these guidelines and recommendations, radiologists and imaging professionals can enhance diagnostic accuracy, reduce variability, and maximise the clinical value of DWI across diverse applications. Key Points This article provides an overview of DWI principles, clinical applications, potential pitfalls, and emerging advances, alongside expert recommendations for optimal implementation. We provide key considerations tailored to specific applications (neuro and whole-body imaging), including protocol optimisation, adherence to established guidelines, and quality assurance measures to minimise artefacts and ensure reproducibility. By following the guidelines and recommendations summarised in this work, radiologists and imaging professionals can enhance diagnostic accuracy, reduce variability, and maximise the clinical value of DWI across diverse applications., The authors state that this work has not received any funding. M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/2 and the Medical Research Council research grant MR/W031566/1. R.P.-L. is supported by ‘la Caixa’ Foundation, a CRIS Cancer Foundation Talent Award (TALENT19-05), the Instituto de Salud Carlos III-Investigación en Salud (PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR), and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). F.G. receives the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010”. I.O.J. is supported by the SNSF Eccellenza fellowship #194260. M.N. is supported by the Swedish Cancer Foundation (FO2024-0335-HK-73) and the Swedish Science Council (2024-04968).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI

  • Palombo, Marco
  • Navarro-Garcia, Daniel
  • Macarro, Carlos
  • Merino Casabiel, Xavier
  • Mast, Richard
  • Grussu, Francesco
  • Grigoriou, Athanasios
  • Bernatowicz, Kinga
  • Casanova-Salas, Irene
  • Barba, Ignasi
  • Simonetti, Sara
  • Serna, Garazi
  • Voronova, Anna
  • Corral Gámez, Juanfra
  • Roson Gradaille, Nuria
  • ESCOBAR, MANUEL
  • Vieito , Maria
  • Toledo, Rodrigo
  • Nuciforo, Paolo
  • Mateo, Joaquin
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
Liver tumour cell; In vivo diffusion MRI, Células tumorales hepáticas; Resonancia magnética de difusión in vivo, Cèl·lules tumorals hepàtiques; Ressonància magnètica de difusió in vivo, Background: Innovative diffusion Magnetic Resonance Imaging (MRI) models enable the non-invasive measurement of cancer biological properties in vivo. However, while cancers frequently spread to the liver, models tailored for liver application and easy to deploy in the clinic are still sought. We fill this gap by delivering a practical, clinically-viable framework for liver tumour diffusion imaging, informing its design through histology. Methods: We compare MRI and histological data from mice and cancer patients, namely: MRI and hemaotxylin-eosin (HE) stains from N = 7 fixed mouse livers; MRI of N = 38 patients suffering from liver solid tumours, N = 18 of whom with HE biopsies. We study five diffusion models, ranking them according to a total MRI-histology correlation score. Afterwards, we test metrics from the top-ranking model on our cohort, assessing their sensitivity to cell proliferation (Ki-67 staining, N = 10), evaluating their association with tumour volume (N = 140 tumours), and comparing them across primary cancer types. Results: We select a dMRI signal model of restricted intra-cellular diffusion with negligible extra-cellular contributions, which maximises radiological-histological correlations (total score: 0.625). The model provides cell size and density estimates that i) correlate with histology (e.g., for cell size: r = 0.44, p = 0.029), ii) are associated to Ki-67 cell proliferation (for MRI cell density: r = 0.80, p = 0.006) and tumour volume (r = 0.40, p < 10-5 for tumour volume regression), and iii) that distinguish melanoma (N = 8) from colorectal cancer (N = 13) (p = 0.011 for intra-cellular fraction). Conclusions: Our biologically meaningful approach may complement standard-of-care radiology, and become a new tool for enhanced cancer characterisation in precision oncology., We thank the whole medical oncology, radiology, pathology, molecular biology, clinical trial, and IT teams at the Vall d’Hebron University Hospital and at the Vall d’Hebron Institute of Oncology in Barcelona (Spain), without whom this study would not have been possible. We are also thankful to the Vall d’Hebron Radiology department and to the ASCIRES CETIR clinical team for their assistance, and to past and present members of the Radiomics group for useful discussion and advice. Finally, we would like to express our sincere gratitude to all patients and their families for dedicating their time to research. VHIO would like to acknowledge: the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support on this research. This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project “PI21/01019” and co-funded by the European Union. Data acquisition was also supported by PREdICT, sponsored by AstraZeneca. This study has been co-funded by the European Regional Development Fund/European Social Fund ‘A way to make Europe’ (to R.P.L.), and by the Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI), funded by the Banco Bilbao Vizcaya Argentaria Foundation Foundation (FBBVA, grant 89/2017). R.P.L is supported by the “la Caixa” Foundation CaixaResearch Advanced Oncology Research Program, the Prostate Cancer Foundation (18YOUN19), ISCIII (PI18/01395), a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation through the XVIII Fero Fellowship for Oncological Research, the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR) and the Generalitat de Catalunya Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). The project that gave rise to these results received the support of a fellowship from”la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010” (funding F.G. and A.V.) and “LCF/BQ/PI20/11760033” (funding I.C.S). I.C.S. also receives the support of the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 847648. This research has received support from the Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP 00182) of the H2020 program (to K.B.). M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/2. A.G. is supported by a Severo Ochoa PhD fellowship (PRE2022-102586). C.M. is funded by the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR). Funding supported personnel, data acquisition and processing, and dissemination. Funders did not influence the content of the manuscript and the decision to submit it in its current form for publication.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy

  • Castillo, Gloria
  • Martinez Perez, Paola
  • Gonzalez Medina, Alberto
  • Vila-Casadesús, Maria
  • Gómez-Rey, Marina
  • Fabregat Franco, Carles
  • TIAN, TIAN
  • Castet, Florian
  • Matito, Judit
  • Miquel Aymar, Josep Maria
  • Nuciforo, Paolo
  • Perez-Lopez, Raquel
  • Vivancos, Ana
  • SIERRA, ALEXANDRE
  • Macarulla, Teresa
Liquid biopsy; Cholangiocarcinoma; Targeted therapy, Biopsia líquida; Colangiocarcinoma; Terapia dirigida, Biòpsia líquida; Colangiocarcinoma; Teràpia dirigida, Purpose: FGFR2 fusions occur in 10% to 15% of patients with intrahepatic cholangiocarcinoma (iCCA), potentially benefiting from FGFR inhibitors (FGFRi). We aimed to assess the feasibility of detecting FGFR2 fusions in plasma and explore plasma biomarkers for managing FGFRi treatment. Experimental design: We conducted a retrospective study in 18 patients with iCCA and known FGFR2 fusions previously identified in tissue samples from prior FGFRi treatment. Both tissue and synchronous plasma samples were analyzed using a custom hybrid capture gene panel with next-generation sequencing (VHIO-iCCA panel) and validated against commercial vendor results. Longitudinal plasma analysis during FGFRi was performed. Subsequently, we explored the correlation between plasma biomarkers, liver enzymes, tumor volume, and clinical outcomes. Results: Sixteen patients (88.9%) were positive for FGFR2 fusion events in plasma. Remarkably, the analysis of plasma suggests that lower levels of ctDNA are linked to clinical benefits from targeted therapy and result in improved progression-free survival and overall survival. Higher concentrations of cell-free DNA before FGFRi treatment were linked to worse overall survival, correlating with impaired liver function and indicating compromised cell-free DNA removal by the liver. Additionally, increased ctDNA or the emergence of resistance mutations allowed earlier detection of disease progression compared with standard radiologic imaging methods. Conclusions: VHIO-iCCA demonstrated accurate detection of FGFR2 fusions in plasma. The integration of information from various plasma biomarkers holds the potential to predict clinical outcomes and identify treatment failure prior to radiologic progression, offering valuable guidance for the clinical management of patients with iCCA., This study was supported by Incyte Corporation (Wilmington, DE; project title: “Identification of FGFR2 alterations by liquid biopsy and correlation with tissue biopsies in patients with cholangiocarcinoma”), the Asociación Española contra el Cáncer (AECC, Spain), and the FERO Foundation. A. Gonzalez-Medina is supported by the grant FJC2019-039770-I funded by Agencia Estatal de Investigación of Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033, Spain). R. Pérez-López. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Prostate Cancer Foundation (18YOUN19), and the Asociación Española Contra el Cáncer (AECC; PRYCO211023SERR, funding CM). A. Vivancos is supported by the Instituto de Salud Carlos III-investigación en Salud (PI20/01112). Some pictures were created with BioRender.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A framework for artificial intelligence in cancer research and precision oncology

  • Perez-Lopez, Raquel
  • Reis-Filho, Jorge S.
  • Kather, Jakob Nikolas
Artificial intelligence; Precision oncology, Intel·ligència artificial; Oncologia de precisió, Inteligencia artificial; Oncología de precisión, R.P.L. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019), the Prostate Cancer Foundation (18YOUN19) and the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR, funding C.M.). J.N.K. is supported by the German Federal Ministry of Health (DEEP LIVER, ZMVI1-2520DAT111) and the Max-Eder-Program of the German Cancer Aid (grant #70113864), the German Federal Ministry of Education and Research (PEARL, 01KD2104C; CAMINO, 01EO2101; SWAG, 01KD2215A; TRANSFORM LIVER, 031L0312A; TANGERINE, 01KT2302 through ERA-NET Transcan), the German Academic Exchange Service (SECAI, 57616814), the German Federal Joint Committee (Transplant.KI, 01VSF21048) the European Union’s Horizon Europe and innovation program (ODELIA, 101057091; GENIAL, 101096312) and the National Institute for Health and Care Research (NIHR, NIHR213331) Leeds Biomedical Research Centre. JSR-F is funded in part by the Breast Cancer Research Foundation, a Susan G Komen Leadership grant, an NIH/NCI P50 CA247749 01 grant, and an NIH/NCI grant No. P30CA008748. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Enhancing Tumor Microstructural Quantification With Machine Learning and Diffusion-Relaxation MRI

  • Macarro, Carlos
  • Bernatowicz, Kinga
  • García Ruiz, Alonso
  • Monreal-Agüero, Camilo
  • Corral Gámez, Juanfra
  • Merino Casabiel, Xavier
  • Mast, Richard
  • Serna, Garazi
  • Simonetti, Sara
  • Roson Gradaille, Nuria
  • Vieito , Maria
  • ESCOBAR, MANUEL
  • Toledo, Rodrigo
  • Nuciforo, Paolo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Grussu, Francesco
Cuantificación microestructural de tumores; Aprendizaje automático; Resonancia magnética de difusión-relajación, Quantificació microestructural del tumor; Aprenentatge automàtic; Ressonància magnètica de difusió-relaxació, Tumor microstructural quantification; Machine learning; Diffusion-relaxation magnetic resonance imaging, We thank the whole medical oncology, radiology, pathology, molecular biology, clinical trial, and IT teams at the Vall d'Hebron Campus. We would also like to express our sincere gratitude to all patients and their families for dedicating their time to research. VHIO acknowledges the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support. This research has been supported by PREdICT, sponsored by AstraZeneca. This study has been co-funded by the European Regional Development Fund/European Social Fund “A way to make Europe” (to R.P.L.). RPL is supported by “la Caixa” Foundation, the Prostate Cancer Foundation (18YOUN19), a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation through the XVIII Fero Fellowship for Oncological Research, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR) and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). This research has been funded by the CaixaResearch Advanced Oncology Research Program supported by “La Caixa” Foundation (to R.P.L.). The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010”, funding F.G. This research has received support from the Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP 00182) of the H2020 program (to K.B.). C.M. is supported by the Asociación Española Contra el Cancer (PRYCO211023SERR). VHIO is also grateful to the Generalitat de Catalunya, Comissió Interdepartamental de Recerca i Innovació Tecnològica.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer

  • Balaguer-Montero, Maria
  • Marcos Morales, Adrià
  • Leiva, David
  • Atlagich, Luz M.
  • Staikoglou, Nikolaos
  • Monreal, Camilo
  • Hernando, Jorge
  • Garcia-Alvarez, Alejandro
  • Ligero, Marta
  • Zatse, Christina
  • Viaplana, Cristina
  • Mateo, Joaquin
  • Salvà, Francesc
  • Capdevila Castillon, Jaume
  • Dienstmann, Rodrigo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Elez, Elena
Deep learning; Imaging; Liver tumors, Aprendizaje profundo; Imágenes; Tumores hepáticos, Aprenentatge profund; Imatges; Tumors hepàtics, Liver tumors, whether primary or metastatic, significantly impact the outcomes of patients with cancer. Accurate identification and quantification are crucial for effective patient management, including precise diagnosis, prognosis, and therapy evaluation. We present SALSA (system for automatic liver tumor segmentation and detection), a fully automated tool for liver tumor detection and delineation. Developed on 1,598 computed tomography (CT) scans and 4,908 liver tumors, SALSA demonstrates superior accuracy in tumor identification and volume quantification, outperforming state-of-the-art models and inter-reader agreement among expert radiologists. SALSA achieves a patient-wise detection precision of 99.65%, and 81.72% at lesion level, in the external validation cohorts. Additionally, it exhibits good overlap, achieving a dice similarity coefficient (DSC) of 0.760, outperforming both state-of-the-art and the inter-radiologist assessment. SALSA’s automatic quantification of tumor volume proves to have prognostic value across various solid tumors (p = 0.028). SALSA’s robust capabilities position it as a potential medical device for automatic cancer detection, staging, and response evaluation., R.P.-L. is supported by “la Caixa” Foundation, a CRIS Cancer Foundation Talent Award (TALENT19-05), the Fero Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR), and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response

  • Navarro-Garcia, Daniel
  • Klümper, Niklas
  • Macarro, Carlos
  • Sanz, Marta
  • Alonso, Guzman
  • Lostes Bardaji, M Julia
  • Grussu, Francesco
  • Zatse, Christina
  • Hernando-Calvo, Alberto
  • Vieito , Maria
  • Brana, Irene
  • Mirallas, Oriol
  • Galvao, Vladimir
  • Pretelli, Giulia
  • Oberoi, Arjun
  • Toledo, Rodrigo
  • Nuciforo, Paolo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
Biomarcador; Inhibidor de puntos de control inmunitario; Inmunoterapia, Biomarcador; Inhibidor del punt de control immunitari; Immunoteràpia, Biomarker; Immune checkpoint inhibitor; Immunotherapy, Background The C-reactive protein (CRP) flare response, an indicator of early immune activation, has emerged as a promising and cost-effective biomarker for predicting response to immune checkpoint inhibitors (ICIs) across various tumor types. This study evaluates the utility of CRP dynamics as a tumor-agnostic biomarker and integrates systemic inflammatory markers with advanced multiparametric MRI metrics to uncover the biological mechanisms underlying the CRP flare phenomenon and its relationship with treatment response. Methods Patients were stratified into three groups based on CRP kinetics: (1) flare-responders, characterized by an initial doubling of baseline CRP followed by a decrease below baseline; (2) CRP responders, defined as patients with no flare increase but a CRP reduction of at least 30% below baseline and (3) CRP non-responders. Multiparametric MRI was performed at baseline, early (1–3 weeks), and intermediate (6–8 weeks) time points to assess tumor size and microstructural features, including cell density and vascularization. Clinical benefit and survival outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed using Kaplan-Meier curves and log-rank tests. Cox regression analyses were performed to identify independent predictors of clinical outcomes, while intergroup differences in MRI metrics were assessed using Wilcoxon rank-sum and Kruskal-Wallis tests. Results Among the 121 evaluable patients with solid tumors enrolled in the PREDICT trial, CRP flare-responders demonstrated significantly longer PFS (5.6 months) and OS (12.1 months) compared with responders (PFS: 3.4 months, OS: 8.0 months) and non-responders (PFS: 3.2 months, OS: 6.7 months; p=0.01 and p<0.01, respectively). Additionally, clinical benefit was achieved in 50% of flare-responders, compared with 13% of responders (p=0.05) and 23% of non-responders (p<0.01). Tumor growth was interrupted early after treatment initiation in CRP flare-responders, whereas non-responders exhibited marked increases in tumor size. In the pilot subset of 33 patients with MRI data, diffusion MRI revealed stable or increased apparent diffusion coefficient values in CRP flare-responders, indicative of reduced tumor cellularity just after 1–3 weeks of treatment. Conclusions This study highlights the potential of combining early CRP dynamics with non-invasive imaging metrics to identify ICI responders as early as 2 weeks after treatment initiation. By integrating systemic inflammatory biomarkers with MRI-derived insights into tumor size and microstructural changes, these findings optimize therapeutic strategies and advance understanding of immunotherapy-driven tumor dynamics., This research has been supported by PREDICT sponsored by AstraZeneca. RP-L is also supported by a CRIS Foundation Talent Award (TALENT19-05), Asociacion Espanola Contra el Cancer (AECC) (PRYCO211023SERR), the FERO Foundation, “la Caixa” Foundation, Instituto de Salud Carlos III-Investigación en Salud (PI21/01019), and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). FG receives the support of a fellowship from "la Caixa" Foundation (ID 100010434). The fellowship code is "LCF/BQ/PR22/11920010". Vall d’Hebron Institut d’Oncologia (VHIO) authors would like to acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for financial support as a Centre of Excellence Severo Ochoa (CEX2020-001024-S/AEI/ 10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, and the Generalitat de Catalunya CERCA Programme for their support of this research. We would like to acknowledge all the patients who participated in this and other clinical research projects for their contribution to science. AHC would like to acknowledge Contrato Rio Hortega 2024 and Beca Gilead a la Investigación Biomedica.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking?

  • Gielen, Bente
  • Prior, Olivia
  • Ligero, Marta
  • Dienstmann, Rodrigo
  • Nuciforo, Paolo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Cresta Morgado, Pablo
  • Navarro Garces, Victor
Biomarkers; Immunotherapy; Cancer, Biomarcadors; Immunoteràpia; Càncer, Biomarcadores; Inmunoterapia; Cáncer, The search for understanding immunotherapy response has sparked interest in diverse areas of oncology, with artificial intelligence (AI) and radiomics emerging as promising tools, capable of gathering large amounts of information to identify suitable patients for treatment. The application of AI in radiology has grown, driven by the hypothesis that radiology images capture tumor phenotypes and thus could provide valuable insights into immunotherapy response likelihood. However, despite the rapid growth of studies, no algorithms in the field have reached clinical implementation, mainly due to the lack of standardized methods, hampering study comparisons and reproducibility across different datasets. In this review, we performed a comprehensive assessment of published data to identify sources of variability in radiomics study design that hinder the comparison of the different model performance and, therefore, clinical implementation. Subsequently, we conducted a use-case meta-analysis using homogenous studies to assess the overall performance of radiomics in estimating programmed death-ligand 1 (PD-L1) expression. Our findings indicate that, despite numerous attempts to predict immunotherapy response, only a limited number of studies share comparable methodologies and report sufficient data about cohorts and methods to be suitable for meta-analysis. Nevertheless, although only a few studies meet these criteria, their promising results underscore the importance of ongoing standardization and benchmarking efforts. This review highlights the importance of uniformity in study design and reporting. Such standardization is crucial to enable meaningful comparisons and demonstrate the validity of biomarkers across diverse populations, facilitating their implementation into the immunotherapy patient selection process., This research has been funded by the Comprehensive Program of Cancer Immunotherapy & Immunology II (CAIMI-II) supported by the BBVA Foundation (grant 53/2021). RPL is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019), the Prostate Cancer Foundation (18YOUN19) and the Asociacion Española Contra el Cancer (AECC) (PRYCO211023SERR). ML is supported by the PERIS PIF-Salut Grant. OP is supported by a La Caixa INPhINIT Fellowship.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

SpinFlowSim: A blood flow simulation framework for histology-informed diffusion MRI microvasculature mapping in cancer

  • Novikov, Dmitry
  • Grigoriou, Athanasios
  • Bernatowicz, Kinga
  • Simonetti, Sara
  • Serna, Garazi
  • Roson Gradaille, Nuria
  • ESCOBAR, MANUEL
  • Vieito , Maria
  • Nuciforo, Paolo
  • Toledo, Rodrigo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Grussu, Francesco
Cancer; Capillary flow; Diffusion MRI, Cáncer; Flujo capilar; Resonancia magnética de difusión, Càncer; Flux capil·lar; Ressonància magnètica de difusió, Diffusion Magnetic Resonance Imaging (dMRI) sensitises the MRI signal to spin motion. This includes Brownian diffusion, but also flow across intricate networks of capillaries. This effect, the intra-voxel incoherent motion (IVIM), enables microvasculature characterisation with dMRI, through metrics such as the vascular signal fraction or the vascular Apparent Diffusion Coefficient (ADC) . The IVIM metrics, while sensitive to perfusion, are protocol-dependent, and their interpretation can change depending on the flow regime spins experience during the dMRI measurements (e.g., diffusive vs ballistic), which is in general not known for a given voxel. These facts hamper their practical clinical utility, and innovative vascular dMRI models are needed to enable the in vivo calculation of biologically meaningful markers of capillary flow. These could have relevant applications in cancer, as in the assessment of the response to anti-angiogenic therapies targeting tumour vessels. This paper tackles this need by introducing SpinFlowSim, an open-source simulator of dMRI signals arising from blood flow within pipe networks. SpinFlowSim, tailored for the laminar flow patterns within capillaries, enables the synthesis of highly-realistic microvascular dMRI signals, given networks reconstructed from histology. We showcase the simulator by generating synthetic signals for 15 networks, reconstructed from liver biopsies, and containing cancerous and non-cancerous tissue. Signals exhibit complex, non-mono-exponential behaviours, consistent with in vivo signal patterns, and pointing towards the co-existence of different flow regimes within the same network, as well as diffusion time dependence. We also demonstrate the potential utility of SpinFlowSim by devising a strategy for microvascular property mapping informed by the synthetic signals, and focussing on the quantification of blood velocity distribution moments and of an apparent network branching index. These were estimated in silico and in vivo, in healthy volunteers scanned at 1.5T and 3T and in 13 cancer patients, scanned at 1.5T. In conclusion, realistic flow simulations, as those enabled by SpinFlowSim, may play a key role in the development of the next-generation of dMRI methods for microvascular mapping, with immediate applications in oncology., VHIO would like to acknowledge: the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support on this research. This research has been supported by PREdICT, sponsored by AstraZeneca. This study has been co-funded by the European Regional Development Fund/European Social Fund ‘A way to make Europe’ (to R.P.L.), and by the Comprehensive Program of Cancer Immunotherapy and Immunology (CAIMI), funded by the Banco Bilbao Vizcaya Argentaria Foundation Foundation (FBBVA, grant 89/2017). R.P.L. is supported by the “la Caixa” Foundation CaixaResearch Advanced Oncology Research Program, the Prostate Cancer Foundation (18YOUN19), a CRIS Foundation Talent Award (TALENT19-05, the FERO Foundation through the XVIII Fero Fellowship for Oncological Research, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR) and the Generalitat de Catalunya Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178, SGR-Cat2021). The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010” (funding F.G., A.V., and A.G.). This research has received support from the Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP 00182) of the H2020 program (to K.B.). M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/2. A.G. is supported by a Severo Ochoa PhD fellowship (PRE2022-102586). The authors are thankful to the Vall d’Hebron Radiology department and to the ASCIRES CETIR clinical team for their assistance with MRI acquisitions, and to the GE/Siemens clinical scientists for their support with diffusion sequence characterisation. We are also thankful to patients and their families, and to Prof Roser Sala-Llonch from the University of Barcelona for useful discussion and institutional support.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study

  • Ramlee, Syafiq
  • Hulse, David
  • Pérez López, Raquel
  • Sala, Evis
  • Aloj, Luigi
  • Bernatowicz, Kinga
Cancer; Immune cells; Lymphocytes, Cáncer; Células inmunes; Linfocitos, Càncer; Cèl·lules immunitàries; Limfòcits, The tumour immune microenvironment influences the efficacy of immune checkpoint inhibitors. Within this microenvironment are CD8-expressing tumour-infiltrating lymphocytes (CD8+ TILs), which are an important mediator and marker of anti-tumour response. In practice, the assessment of CD8+ TILs via tissue sampling involves logistical challenges. Radiomics, the high-throughput extraction of features from medical images, may offer a novel and non-invasive alternative. We performed a systematic review of the available literature reporting radiomic signatures associated with CD8+ TILs. We also aimed to evaluate the methodological quality of the identified studies using the Radiomics Quality Score (RQS) tool, and the risk of bias and applicability with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Articles were searched from inception until 31 December 2021, in three electronic databases, and screened against eligibility criteria. Twenty-seven articles were included. A wide variety of cancers have been studied. The reported radiomic signatures were heterogeneous, with very limited reproducibility between studies of the same cancer group. The overall quality of studies was found to be less than desirable (mean RQS = 33.3%), indicating a need for technical maturation. Some potential avenues for further investigation are also discussed., This work was supported by the Cancer Research UK (CRUK) Cambridge Centre (CTRQQR-2021\100012) and the CRUK National Cancer Imaging Translational Accelerator (NCITA) (C22479/A28667); additional support was also provided by the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014); the views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care; S.R. is supported by the Brunei “Sultan’s Scholar” scholarship from the Sultan Haji Hassanal Bolkiah Foundation; D.H. is supported by the Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies project (RG96994 and 831514); K.B. is supported by MSCA COFUND Beatriu de Pinós Grant (2019BP/00182); R.P.L. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019) and the Prostate Cancer Foundation (18YOUN19).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

  • Ros Montañá, Fco. Javier
  • Fernández, Jose
  • Moreno-Cárdenas, Ana Belén
  • Arenillas Lallana, Carlota
  • Fasani, Roberta
  • Garcia Rodriguez, Ariadna
  • Gonzalo-Ruiz, Javier
  • Nuciforo, Paolo Giovanni
  • Vivancos Prellezo, Ana
  • Pérez López, Raquel
  • Tabernero, Josep
  • De Almeida Toledo, Rodrigo
  • Comas Navarro, Raquel
  • Dienstmann, Rodrigo
  • Bernatowicz, Kinga
  • Piris-Giménez, Alejandro
  • Elez Fernandez, Mª Elena
  • Villacampa Javierre, Guillermo
Colorectal cancer; Predictive markers; Tumour biomarkers, Cáncer colorrectal; Marcadores predictivos; Biomarcadores tumorales, Càncer colorrectal; Marcadors predictius; Biomarcadors tumorals, Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; P = 0.008), in patients with MSS-RNF43mutated versus MSS-RNF43wild-type tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRCBRAF-V600E tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients., VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment, the FERO Foundation for their funding support, the Consorcio Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, CB16/12/00259) from the Institute of Health Carlos III (ISCIII), Ministry of Science and Innovation, and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 and SLT008/18/00205) for their support on this research. Authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S / AEI / 10.13039 /501100011033). This research is funded by the SCITRON program; Novartis funded the genomics characterization by WES of samples from 28 patients from the discovery cohort and had no influence on data analysis/interpretation or writing of the paper (3003145512 to R.A.T.). S.Li. is financially supported by a Chinese Scholarship Council PhD fellowship (201909370083 to S. Li). R.P.-L. is supported by a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019 to R.P.-L.) and the Prostate Cancer Foundation (Young Investigator Award). This work was supported by the Miguel Servet-I Research Award from ISCIII of the Ministry of Economy (CP17/00199 to R.A.T.), the Olga Torres Foundation Award to emerging researchers (2601 to R.A.T.), the ISCIII-FEDER (PI17/00947 and PI20/00968 to E.E.), and the Fundación AECC (CLSEN19001ELEZ to E.E.) and Ministry of Science and Innovation (Europa Redes y Gestores, ECT2020-000827 to E.E.).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

  • Ligero, Marta
  • El Nahhas, Omar
  • SANSANO, IRENE
  • Mauchanski, Siarhei
  • Serna, Garazi
  • Viaplana, Cristina
  • Toledo, Rodrigo
  • Dienstmann, Rodrigo
  • Ramon y Cajal, Santiago
  • GARRALDA, Elena
  • Nuciforo, Paolo
  • Perez-Lopez, Raquel
Deep learning; Immunotherapy; Solid tumors, Aprenentatge profund; Immunoteràpia; Tumors sòlids, Aprendizaje profundo; Inmunoterapia; Tumores sólidos, Programmed death-ligand 1 (PD-L1) IHC is the most commonly used biomarker for immunotherapy response. However, quantification of PD-L1 status in pathology slides is challenging. Neither manual quantification nor a computer-based mimicking of manual readouts is perfectly reproducible, and the predictive performance of both approaches regarding immunotherapy response is limited. In this study, we developed a deep learning (DL) method to predict PD-L1 status directly from raw IHC image data, without explicit intermediary steps such as cell detection or pigment quantification. We trained the weakly supervised model on PD-L1–stained slides from the non–small cell lung cancer (NSCLC)-Memorial Sloan Kettering (MSK) cohort (N = 233) and validated it on the pan-cancer-Vall d'Hebron Institute of Oncology (VHIO) cohort (N = 108). We also investigated the performance of the model to predict response to immune checkpoint inhibitors (ICI) in terms of progression-free survival. In the pan-cancer-VHIO cohort, the performance was compared with tumor proportion score (TPS) and combined positive score (CPS). The DL model showed good performance in predicting PD-L1 expression (TPS ≥ 1%) in both NSCLC-MSK and pan-cancer-VHIO cohort (AUC 0.88 ± 0.06 and 0.80 ± 0.03, respectively). The predicted PD-L1 status showed an improved association with response to ICIs [HR: 1.5 (95% confidence interval: 1–2.3), P = 0.049] compared with TPS [HR: 1.4 (0.96–2.2), P = 0.082] and CPS [HR: 1.2 (0.79–1.9), P = 0.386]. Notably, our explainability analysis showed that the model does not just look at the amount of brown pigment in the IHC slides, but also considers morphologic factors such as lymphocyte conglomerates. Overall, end-to-end weakly supervised DL shows potential for improving patient stratification for cancer immunotherapy by analyzing PD-L1 IHC, holistically integrating morphology and PD-L1 staining intensity. Significance: The weakly supervised DL model to predict PD-L1 status from raw IHC data, integrating tumor staining intensity and morphology, enables enhanced patient stratification in cancer immunotherapy compared with traditional pathologist assessment., J.N. Kather is supported by the German Federal Ministry of Health (DEEP LIVER, ZMVI1-2520DAT111) and the Max-Eder-Programme of the German Cancer Aid (grant no. 70113864), the German Federal Ministry of Education and Research (PEARL, 01KD2104C; CAMINO, 01EO2101; SWAG, 01KD2215A; TRANSFORM LIVER, 031L0312A; TANGERINE, 01KT2302 through ERA-NET Transcan), the German Academic Exchange Service (SECAI, 57616814), the German Federal Joint Committee (Transplant.KI, 01VSF21048) the European Union's Horizon Europe and innovation programme (ODELIA, 101057091; GENIAL, 101096312) and the National Institute for Health and Care Research (NIHR, NIHR213331) Leeds Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. R. Perez-Lopez is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019) and the Prostate Cancer Foundation (18YOUN19). M. Ligero is supported by the PERIS PIF-Salut Grant. As per the ICMJE guidelines of April 2023, we hereby disclose that the following artificial intelligence tools were used to write this article: ChatGPT-4 for checking and correcting spelling and grammar.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient

  • Zacchi, Francesca
  • Semidey Raven, Maria Eugenia
  • Maldonado, Xavier
  • Perez-Lopez, Raquel
  • Mateo, Joaquin
  • Macarena, Gonzalez
  • Carles, Joan
Bone metastases; Bone response; Metastatic castration-resistant prostate cancer, Metástasis óseas; Respuesta ósea; Cáncer de próstata resistente a la castración metastásico, Metàstasis òssies; Resposta òssia; Càncer de pròstata resistent a la castració metastàtic, Despite the development of new therapies in the last few years, metastatic prostate cancer (PCa) is still a lethal disease. Radium-223 (Ra-223) is approved for patients with advanced castration-resistant prostate cancer (CRPC) with bone metastases and no visceral disease. However, patients' outcomes are heterogenous, and there is lack of validated predictive biomarkers of response, while biomarkers for early identification of patients who benefit from treatment are limited. This case report describes a remarkable and durable response to Ra-223 in a CRPC patient with bone metastases who had rapidly progressed to many previous therapies; this response is now lasting for 5 years even after having stopped backbone androgen deprivation therapy (ADT). Here, we present the clinical course of this exceptional response, as well as comprehensive genomic and histopathology analyses on sequential biopsies acquired before and after therapy. Additionally, we review current knowledge on predictive and response biomarkers to Ra-223 in metastatic prostate cancer., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors acknowledge funding from CRIS Cancer Foundation (grant TCL_2020-10 to JM) and Fundación AECC (LABAE20019MATE to JM) and FERO Foundation. RP-L is supported by LaCaixa Foundation, a CRIS Foundation Talent Award TALENT19-05, the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud PI18/01395 and PI21/01019 and the Prostate Cancer Foundation 18YOUN19.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction

  • Zatse, Christina
  • Garazi, Serna
  • Bernatowicz, Kinga
  • Amat Ferrer, Ramon
  • Prior, Olivia
  • Frigola Rissech, Joan
  • Ligero, Marta
  • Grussu, Francesco
  • Nuciforo, Paolo
  • Toledo, Rodrigo
  • ESCOBAR, MANUEL
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • FELIP, ENRIQUETA
Computed tomography; Immunotherapy; Tumor microenvironment, Tomografía computarizada; Inmunoterapia; Microambiente tumoral, Tomografia computeritzada; Immunoteràpia; Microambient tumoral, Background: The efficacy of immune checkpoint inhibitors (ICIs) depends on the tumor immune microenvironment (TIME), with a preference for a T cell-inflamed TIME. However, challenges in tissue-based assessments via biopsies have triggered the exploration of non-invasive alternatives, such as radiomics, to comprehensively evaluate TIME across diverse cancers. To address these challenges, we develop an ICI response signature by integrating radiomics with T cell-inflamed gene-expression profiles. Methods: We conducted a pan-cancer investigation into the utility of radiomics for TIME assessment, including 1360 tumors from 428 patients. Leveraging contrast-enhanced CT images, we characterized TIME through RNA gene expression analysis, using the T cell-inflamed gene expression signature. Subsequently, a pan-cancer CT-radiomic signature predicting inflamed TIME (CT-TIME) was developed and externally validated. Machine learning was employed to select robust radiomic features and predict inflamed TIME. The study also integrated independent cohorts with longitudinal CT images, baseline biopsies, and comprehensive immunohistochemistry panel evaluation to assess the pan-cancer biological associations, spatiotemporal landscape and clinical utility of the CT-TIME. Results: The CT-TIME signature, comprising four radiomic features linked to a T-cell inflamed microenvironment, demonstrated robust performance with AUCs (95% CI) of 0.85 (0.73 to 0.96) (training) and 0.78 (0.65 to 0.92) (external validation). CT-TIME scores exhibited positive correlations with CD3, CD8, and CD163 expression. Intrapatient analysis revealed considerable heterogeneity in TIME between tumors, which could not be assessed using biopsies. Evaluation of aggregated per-patient CT-TIME scores highlighted its promising clinical utility for dynamically assessing the immune microenvironment and predicting immunotherapy response across diverse scenarios in advanced cancer. Despite demonstrating progression disease at the first follow-up, patients within the inflamed status group, identified by CT-TIME, exhibited significantly prolonged progression-free survival (PFS), with some surpassing 5 months, suggesting a potential phenomenon of pseudoprogression. Cox models using aggregated CT-TIME scores from baseline images revealed a statistically significant reduction in the risk of PFS in the pan-cancer cohort (HR 0.62, 95% CI 0.44 to 0.88, p=0.007), and Kaplan-Meier analysis further confirmed substantial differences in PFS between patients with inflamed and uninflamed status (log-rank test p=0.009). Conclusions: The signature holds promise for impacting clinical decision-making, pan-cancer patient stratification, and treatment outcomes in immune checkpoint therapies., KB is supported by MSCA COFUND Beatriu de Pinós Grant (2019BP/00182). FG receives the support of a fellowship from LaCaixa Foundation (ID 100010434). The fellowship code is LCF/BQ/PR22/11920010. RP-L is supported by CRIS Cancer Foundation (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019) and the Prostate Cancer Foundation (18YOUN19). OP was funded by Fundació “LaCaixa” (ID 100010434, code LCF/BQ/DR21/11880027).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

An accessible deep learning tool for voxel-wise classification of brain malignancies from perfusion MRI

  • Garcia Ruiz, Alonso
  • Pons-Escoda, Albert
  • Naval-Baudin, Pablo
  • Monreal-Aguero, Camilo
  • Hermann, Gretchen
  • Grussu, Francesco
  • Ligero, Marta
  • Perez-Lopez, Raquel
Deep learning; Glioblastoma; Perfusion MRI, Aprenentatge profund; Glioblastoma; Ressonància magnètica de perfusió, Aprendizaje profundo; Glioblastoma; Resonancia magnética de perfusión, Noninvasive differential diagnosis of brain tumors is currently based on the assessment of magnetic resonance imaging (MRI) coupled with dynamic susceptibility contrast (DSC). However, a definitive diagnosis often requires neurosurgical interventions that compromise patients' quality of life. We apply deep learning on DSC images from histology-confirmed patients with glioblastoma, metastasis, or lymphoma. The convolutional neural network trained on ∼50,000 voxels from 40 patients provides intratumor probability maps that yield clinical-grade diagnosis. Performance is tested in 400 additional cases and an external validation cohort of 128 patients. The tool reaches a three-way accuracy of 0.78, superior to the conventional MRI metrics cerebral blood volume (0.55) and percentage of signal recovery (0.59), showing high value as a support diagnostic tool. Our open-access software, Diagnosis In Susceptibility Contrast Enhancing Regions for Neuro-oncology (DISCERN), demonstrates its potential in aiding medical decisions for brain tumor diagnosis using standard-of-care MRI., This project was supported by “La Caixa” Foundation (RTI2018-095209-B-C21) and the Spanish Ministry of Science and Innovation (FIS-G64384969). R.P.-L. is supported by the Prostate Cancer Foundation Young Investigator Award, the FERO Foundation, the CRIS Foundation Talent Award (TALENT19-05), the Instituto de Salud Carlos III Investigacion en Salud (PI21/01019), and the Asociacion Espanola Contra el Cancer (PRYCO211023SERR). F.G. was funded by the Government of Catalonia (Beatriu de Pinos 2020 00117 BP) and by the Fundacio LaCaixa (ID 100010434, code LCF/BQ/PR22/11920010). C.M. and A.P.-E. acknowledge support from the Instituto de Salud Carlos III-Investigación en Salud (PI20/00360). We would like to express our sincere appreciation to Javier Carmona for his valuable support and assistance in reviewing the manuscript.